SPOTLIGHT -
EP. 1: An Update on Molecular Testing in Colorectal Cancer
EP. 2: Liquid- Vs Tissue-Based Testing in Colorectal Cancer
EP. 3: Finding Actionable Biomarkers in Colorectal Cancer
EP. 4: Optimizing Care in Metastatic Colorectal Cancer
EP. 5: Multidisciplinary Approaches in Metastatic Colorectal Cancer
EP. 6: Goals of Systemic Therapy in Colorectal Cancer
EP. 7: Neoadjuvant and Adjuvant Therapy in Metastatic Colorectal Cancer
EP. 8: Colorectal Cancer: Choosing a Biologic
EP. 9: Right- Versus Left-Sided Colorectal Tumors and Survival
EP. 10: Decisions in Colorectal Cancer Maintenance Therapy and Sequencing
EP. 11: Goals of Therapy in Refractory Colorectal Cancer
EP. 12: Colorectal Cancer: Regorafenib Patient Selection and Dosing
EP. 13: Role of TAS-102 (Trifluridine/tipiracil) in Advanced Colorectal Cancer
EP. 14: Referring Patients with Colorectal Cancer to Clinical Trials
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
